John D Minna Selected Research

Peptoids

1/2022	Unbiased peptoid cell screen identifies a peptoid targeting newly appeared cell surface vimentin on tumor transformed early lung cancer cells.
10/2019	Unbiased peptoid combinatorial cell screen identifies plectin protein as a potential biomarker for lung cancer stem cells.
5/2016	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.
12/2015	Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John D Minna Research Topics

Disease

205	Neoplasms (Cancer) 01/2022 - 01/2002
170	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2002
92	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 02/2002
27	Adenocarcinoma of Lung 01/2022 - 01/2005
22	Carcinogenesis 01/2021 - 02/2003
20	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2021 - 12/2002
17	Breast Neoplasms (Breast Cancer) 01/2018 - 08/2002
16	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2002
13	Adenocarcinoma 03/2021 - 01/2003
10	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019 - 01/2008
8	Carcinoma (Carcinomatosis) 06/2014 - 06/2002
5	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 06/2009
5	COVID-19 01/2022 - 01/2021
4	Hypoxia (Hypoxemia) 01/2021 - 08/2011
4	Inflammation (Inflammations) 09/2014 - 04/2006
3	Pneumonia (Pneumonitis) 01/2018 - 08/2010
3	Neuroblastoma 02/2015 - 09/2003
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2007 - 03/2004
3	Prostatic Neoplasms (Prostate Cancer) 12/2006 - 02/2002
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 04/2010
2	Communicable Diseases (Infectious Diseases) 11/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

52	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2002
33	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2002
28	DNA (Deoxyribonucleic Acid)IBA 05/2019 - 06/2002
27	Messenger RNA (mRNA)IBA 01/2021 - 07/2002
25	Pharmaceutical PreparationsIBA 12/2021 - 02/2002
24	ErbB Receptors (EGF Receptor)IBA 02/2015 - 11/2004
23	Biological ProductsIBA 07/2021 - 01/2002
19	LigandsIBA 01/2021 - 12/2002
15	Transcription Factors (Transcription Factor)IBA 01/2022 - 02/2002
15	Small Interfering RNA (siRNA)IBA 01/2020 - 05/2004
10	MicroRNAs (MicroRNA)IBA 01/2021 - 11/2007
9	Phosphotransferases (Kinase)IBA 01/2022 - 03/2005
8	Tyrosine Kinase InhibitorsIBA 08/2010 - 02/2006
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2007 - 03/2005
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 07/2004
7	RNA (Ribonucleic Acid)IBA 04/2018 - 09/2003
7	Peptides (Polypeptides)IBA 05/2016 - 12/2003
6	Indicators and Reagents (Reagents)IBA 01/2022 - 12/2003
6	PlatinumIBA 12/2021 - 01/2008
6	EnzymesIBA 01/2021 - 04/2015
6	Estrogen ReceptorsIBA 01/2018 - 01/2008
6	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2017 - 11/2009
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2014 - 01/2005
6	Gefitinib (Iressa)FDA Link 08/2010 - 08/2005
5	AntibodiesIBA 01/2022 - 04/2005
5	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2020 - 08/2010
5	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2018 - 06/2002
5	Decitabine FDA Link 12/2006 - 09/2002
4	NucleotidesIBA 01/2022 - 03/2013
4	PeptoidsIBA 01/2022 - 12/2015
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
4	Histones (Histone)IBA 01/2021 - 02/2006
4	SmokeIBA 08/2018 - 01/2003
4	CholesterolIBA 01/2018 - 11/2004
4	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 10/2006
4	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 06/2014 - 01/2003
4	Nicotine FDA Link 06/2014 - 01/2003
4	Formaldehyde (Formol)FDA Link 02/2013 - 08/2002
4	Cyclin-Dependent Kinase Inhibitor p16IBA 12/2011 - 02/2002
4	Cadherins (E-Cadherin)IBA 10/2010 - 11/2002
3	Adenosine Triphosphate (ATP)IBA 01/2022 - 01/2016
3	Membrane Proteins (Integral Membrane Proteins)IBA 11/2021 - 01/2017
3	Peptide Hydrolases (Proteases)FDA Link 03/2021 - 01/2007
3	MethyltransferasesIBA 01/2021 - 07/2002
3	Oxidoreductases (Dehydrogenase)IBA 01/2021 - 01/2018
3	Histone Deacetylase InhibitorsIBA 01/2021 - 01/2006
3	pyrimidineIBA 12/2020 - 01/2017
3	PlasticsIBA 10/2020 - 06/2004
3	Oncogene Proteins (Oncogene Protein)IBA 09/2020 - 01/2007
3	ProteomeIBA 01/2020 - 05/2014
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2018 - 11/2013
3	Mechanistic Target of Rapamycin Complex 1IBA 09/2018 - 07/2014
3	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2017 - 05/2004
3	LipidsIBA 05/2016 - 07/2010
3	MK 2206IBA 09/2013 - 11/2010
3	Protein Isoforms (Isoforms)IBA 12/2012 - 05/2002
3	AZD 6244IBA 05/2011 - 11/2009
3	CaspasesIBA 11/2010 - 10/2006
3	Epidermal Growth Factor (EGF)IBA 11/2007 - 02/2005
3	AgarIBA 02/2006 - 05/2004
3	H-cadherin (T-cadherin)IBA 08/2005 - 11/2003
3	Cyclin D2IBA 01/2005 - 10/2003
2	LuciferasesIBA 01/2022 - 06/2009
2	NADP (NADPH)IBA 01/2022 - 01/2019
2	NucleosidesIBA 01/2022 - 01/2018
2	TOR Serine-Threonine KinasesIBA 01/2022 - 08/2009
2	Acetyl Coenzyme A (Acetyl-CoA)IBA 01/2022 - 12/2010
2	VimentinIBA 01/2022 - 10/2010
2	Inosine Monophosphate (IMP)IBA 01/2021 - 01/2018
2	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 12/2010
2	GuanosineIBA 01/2021 - 01/2018
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2016

Therapy/Procedure

79	Therapeutics 12/2021 - 02/2002
23	Drug Therapy (Chemotherapy) 12/2021 - 02/2002
9	Chemoprevention 01/2022 - 01/2002
7	Radiotherapy 07/2021 - 04/2007
5	Adjuvant Chemotherapy 01/2019 - 07/2010
3	Immunotherapy 11/2020 - 01/2018
3	Precision Medicine 12/2018 - 12/2010